50,000 Shares in Arvinas, Inc. $ARVN Bought by BML Capital Management LLC

BML Capital Management LLC bought a new stake in Arvinas, Inc. (NASDAQ:ARVN) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 50,000 shares of the company’s stock, valued at approximately $426,000. Arvinas comprises about 0.3% of BML Capital Management LLC’s investment portfolio, making the stock its 17th largest holding. BML Capital Management LLC owned 0.08% of Arvinas as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also modified their holdings of ARVN. Geode Capital Management LLC boosted its holdings in shares of Arvinas by 3.1% in the 2nd quarter. Geode Capital Management LLC now owns 1,585,092 shares of the company’s stock valued at $11,668,000 after buying an additional 48,296 shares in the last quarter. Acadian Asset Management LLC boosted its stake in Arvinas by 791.1% in the second quarter. Acadian Asset Management LLC now owns 1,427,832 shares of the company’s stock valued at $10,498,000 after acquiring an additional 1,267,593 shares in the last quarter. Millennium Management LLC grew its holdings in Arvinas by 208.4% in the first quarter. Millennium Management LLC now owns 1,310,326 shares of the company’s stock worth $9,198,000 after purchasing an additional 885,483 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Arvinas by 108.3% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 902,925 shares of the company’s stock worth $6,339,000 after purchasing an additional 469,394 shares in the last quarter. Finally, Monaco Asset Management SAM lifted its holdings in shares of Arvinas by 185.6% during the 2nd quarter. Monaco Asset Management SAM now owns 900,936 shares of the company’s stock valued at $6,631,000 after purchasing an additional 585,477 shares during the last quarter. 95.19% of the stock is owned by hedge funds and other institutional investors.

Arvinas Trading Down 3.6%

Shares of NASDAQ:ARVN opened at $11.99 on Monday. Arvinas, Inc. has a twelve month low of $5.90 and a twelve month high of $19.05. The company has a market cap of $770.00 million, a PE ratio of -14.80 and a beta of 1.88. The company’s 50 day moving average is $12.36 and its 200 day moving average is $10.42.

Insider Buying and Selling

In related news, CFO Andrew Saik sold 5,134 shares of the business’s stock in a transaction on Friday, February 13th. The shares were sold at an average price of $11.89, for a total transaction of $61,043.26. Following the completion of the transaction, the chief financial officer directly owned 159,267 shares in the company, valued at $1,893,684.63. The trade was a 3.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Randy Teel sold 4,403 shares of the company’s stock in a transaction on Friday, February 13th. The shares were sold at an average price of $11.89, for a total transaction of $52,351.67. Following the completion of the sale, the chief executive officer directly owned 154,482 shares in the company, valued at approximately $1,836,790.98. The trade was a 2.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 16,238 shares of company stock valued at $193,070 over the last 90 days. Insiders own 4.73% of the company’s stock.

Analyst Upgrades and Downgrades

ARVN has been the topic of several research analyst reports. Wall Street Zen upgraded Arvinas from a “sell” rating to a “hold” rating in a research note on Sunday. Wells Fargo & Company dropped their price target on Arvinas from $16.00 to $15.00 and set an “overweight” rating on the stock in a research note on Thursday, November 6th. Wedbush reaffirmed a “neutral” rating and issued a $9.00 price objective on shares of Arvinas in a research report on Thursday, November 6th. Barclays boosted their target price on shares of Arvinas from $16.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. Finally, Stephens upped their price target on shares of Arvinas from $14.00 to $15.00 and gave the company an “overweight” rating in a research note on Monday, November 10th. Ten investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Arvinas has an average rating of “Hold” and a consensus target price of $13.12.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.